In Purdue Pharma L.P. v. Accord Healthcare, Inc., Arun Sharma testified at trial regarding commercial success as an objective indicator of patent non-obviousness on behalf of plaintiff Purdue, which alleged patent infringement in connection with Accord's Paragraph IV Abbreviated New Drug Applications for generic versions of Purdue's OxyContin® opioid pain medication.
Partner with a firm that delivers rigorous economic research and practical advice.
By using this site, you agree to our updated Cookie Policy, Privacy Policy, and our Terms & Conditions.
When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use cookies, please see our Cookie Policy and Privacy Policy.
